CRISPR Therapeutics announced that Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics, has elected to leave CRISPR Therapeutics after nearly a decade of dedicated service to the Company. Dr. Novak?s departure will be effective as of September 15, 2023. As of that date, Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, will succeed Dr. Novak as Chairman of the Board of CRISPR Therapeutics and will continue serving as CEO of the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
58.26 USD | +1.95% | +7.00% | -6.26% |
May. 23 | CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer | MT |
May. 23 | CRISPR Therapeutics Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.26% | 4.85B | |
+46.89% | 56.65B | |
-6.53% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.46% | 26.75B | |
-21.53% | 19.03B | |
+0.82% | 12.28B | |
+23.83% | 12.26B | |
+27.78% | 12.04B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023